Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASFREE: Dasatinib Discontinuation in CP-CML
NCT01850004Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2014
- Primary completion
- Sep 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Jan 2014; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01850004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850004.